[{"orgOrder":0,"company":"Inspirna","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"RGX-104","moa":"||Liver X receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Inspirna","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Inspirna \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Inspirna \/ Inapplicable"},{"orgOrder":0,"company":"Inspirna","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Irinotecan","moa":"||SLC6A8\/CKB pathway","graph1":"Oncology","graph2":"Phase I","graph3":"Inspirna","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Inspirna \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Inspirna \/ Inapplicable"},{"orgOrder":0,"company":"Inspirna","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Irinotecan","moa":"||SLC6A8\/CKB pathway","graph1":"Oncology","graph2":"Phase I","graph3":"Inspirna","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Inspirna \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Inspirna \/ Inapplicable"},{"orgOrder":0,"company":"Inspirna","sponsor":"Sands Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Series D Financing","leadProduct":"Irinotecan","moa":"||SLC6A8\/CKB pathway","graph1":"Oncology","graph2":"Phase I","graph3":"Inspirna","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Inspirna \/ Sands Capital","highestDevelopmentStatusID":"6","companyTruncated":"Inspirna \/ Sands Capital"},{"orgOrder":0,"company":"Inspirna","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Irinotecan HCl Trihydrate","moa":"||SLC6A8\/CKB pathway","graph1":"Oncology","graph2":"Phase I","graph3":"Inspirna","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Inspirna \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Inspirna \/ Inapplicable"},{"orgOrder":0,"company":"Inspirna","sponsor":"Merck Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"RGX-202","moa":"||SLC6A8\/CKB pathway","graph1":"Oncology","graph2":"Phase II","graph3":"Inspirna","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Inspirna \/ Merck Group","highestDevelopmentStatusID":"8","companyTruncated":"Inspirna \/ Merck Group"}]

Find Clinical Drug Pipeline Developments & Deals by Inspirna

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          The Aesthetic Show
                          Not Confirmed
                          The Aesthetic Show
                          Not Confirmed

                          Details : Merck gains exclusive rights to RGX-202 (ompenaclid) for RAS-mutated advanced colorectal cancer, with co-development options in the U.S.

                          Product Name : RGX-202

                          Product Type : Other Small Molecule

                          Upfront Cash : $45.0 million

                          April 01, 2024

                          Lead Product(s) : RGX-202,Bevacizumab,Irinotecan Hydrochloride

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Merck Group

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          02

                          The Aesthetic Show
                          Not Confirmed
                          The Aesthetic Show
                          Not Confirmed

                          Details : RGX-104 (abequolixron) is an orally administered small molecule agonist of the Liver X Receptor (LXR) which activates expression of the APOE tumor suppressor protein. Abequolixron is currently being tested in a Phase 1b/2 clinical trial in several lung c...

                          Product Name : RGX-104

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          May 01, 2023

                          Lead Product(s) : RGX-104,Carboplatin,Pembrolizumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          The Aesthetic Show
                          Not Confirmed
                          The Aesthetic Show
                          Not Confirmed

                          Details : Proceeds will support the development of lead candidate RGX-202-01 (“RGX-202”), an oral small molecule inhibitor of SLC6a8 to treat RAS mutant advanced colorectal cancer and RGX-104, an oral small molecule activator of LXR/APOE to treat lung and endo...

                          Product Name : RGX-202-01

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          November 07, 2022

                          Lead Product(s) : RGX-202-01,Irinotecan Hydrochloride,Calcium Folinate

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Sands Capital

                          Deal Size : $50.0 million

                          Deal Type : Series D Financing

                          blank

                          04

                          The Aesthetic Show
                          Not Confirmed
                          The Aesthetic Show
                          Not Confirmed

                          Details : RGX-202-01 is an oral, potential first-in-class small molecule inhibitor of SLC6a8, a creatine transporter that drives colorectal cancer and certain other cancers’ progression.

                          Product Name : RGX-202-01

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          June 28, 2022

                          Lead Product(s) : RGX-202-01,Irinotecan HCl Trihydrate,Calcium Folinate

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          The Aesthetic Show
                          Not Confirmed
                          The Aesthetic Show
                          Not Confirmed

                          Details : RGX-202-01 is an oral, potential first-in-class small molecule inhibitor of SLC6a8, a creatine transporter that drives colorectal cancer and certain other cancers’ progression.

                          Product Name : RGX-202-01

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          May 26, 2022

                          Lead Product(s) : RGX-202-01,Irinotecan Hydrochloride,Calcium Folinate

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          The Aesthetic Show
                          Not Confirmed
                          The Aesthetic Show
                          Not Confirmed

                          Details : RGX-202-01, oral small-molecule inhibitor of SLC6A8 that induces apoptosis of colorectal cancer cell, is being tested in combination with the FOLFIRI and bevacizumab in a Phase 1b clinical trial for 2nd line treatment of patients with cancer whose tumors...

                          Product Name : RGX-202-01

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          April 27, 2022

                          Lead Product(s) : RGX-202-01,Irinotecan Hydrochloride,Calcium Folinate

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank